The meteoric rise of GLP-1 receptor agonists like Ozempic and Wegovy has transformed the landscape of diabetes and obesity management. By mimicking the GLP-1 hormone, these medications regulate blood sugar and significantly slow the passage of food through the digestive tract. However, new clinical insights and patient reports suggest that for those living with Ehlers-Danlos Syndrome (EDS), these benefits may come at a steep physiological cost.
Recent data highlighted by the EDS Clinic and The Middle Aged Zebra suggests that the very mechanism that makes these drugs effective—delayed gastric emptying—can exacerbate the underlying connective tissue vulnerabilities inherent in EDS.
Because EDS affects the structural integrity of the gastrointestinal tract, many patients already struggle with dysmotility, a condition where the muscles of the digestive system do not work properly. Adding a GLP-1 agonist to this “fragile” system can tip the balance toward gastroparesis, a more severe form of stomach paralysis.
While the general risk of gastroparesis remains low across the broader population, the scale of global usage means hundreds of thousands of individuals could be affected. For the EDS community, the risk is disproportionately higher.
READ: Op-Ed: Counterfeit GLP-1 May Be A Short Term Gain, But A Long Term High Risk
A study published in Clinical and Translational Gastroenterology noted that EDS patients are already overrepresented in cases of idiopathic gastroparesis. In online patient forums, roughly half of EDS respondents using these medications reported debilitating side effects, ranging from severe constipation to “miserable” bouts of nausea and vomiting.
The complexity deepens when considering Mast Cell Activation Syndrome (MCAS), a condition frequently comorbid with EDS. In MCAS, mast cells inappropriately release chemicals that cause systemic inflammation and GI distress.
While rare case studies have shown semaglutide occasionally resolving mast cell symptoms, the more common outcome for these complex patients is a worsening of gastrointestinal stability. Experts at the EDS Clinic suggest that in some cases, treating underlying mast cell activation may actually facilitate weight loss naturally, potentially bypassing the need for GLP-1 drugs altogether.
The risks are not limited to EDS alone. Research by Smieszek et al. indicates that women with Polycystic Ovary Syndrome (PCOS) also experience significant delays in gastric emptying when using semaglutide. Similarly, the estimated 50 million people worldwide dealing with Long COVID face unique hurdles.
Post-viral gastroparesis is a documented phenomenon, likely linked to the SARS-CoV-2 virus’s interaction with ACE-2 receptors in the gut. For a Long COVID patient already dealing with autonomic dysfunction, the introduction of a GLP-1 drug may further stall recovery.
Regulatory bodies and medical societies are beginning to catch up to these clinical observations. The FDA recently updated warning labels for Ozempic and similar drugs to include risks of intestinal blockage and gastroparesis.
Furthermore, the American Society of Anesthesiologists now recommends that patients halt these medications a full week prior to any surgery to prevent the risk of food aspiration under anesthesia—a particular concern for EDS patients, who often face unique surgical and wound-healing challenges.
Medical professionals emphasize that while these drugs are a breakthrough for many, they are not a one-size-fits-all solution.
For patients with complex connective tissue or mast cell disorders, the decision to start a GLP-1 agonist requires a careful weighing of the metabolic benefits against the potential for long-term digestive complications.
Please make a small donation to the Tampa Free Press to help sustain independent journalism. Your contribution enables us to continue delivering high-quality, local, and national news coverage.
Sign up: Subscribe to our free newsletter for a curated selection of top stories delivered straight to your inbox
